Sprycel beats Gleevec in pivotal trial in newly diagnosed CML
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's second-generation BCR-ABL inhibitor Sprycel (dasatinib) showed superior complete response rates to the standard of care in chronic phase chronic myeloid leukaemia (CML), Novartis's Gleevec (imatinib), and could become a new first-line treatment option in the disease, according to the Phase III DASISION data presented at the ASCO meeting in Chicago and simultaneously published in the NEJM.